Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CBX7 | O95931 | 3/20 | 0.40 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.40 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL423770 | 0.99 | ACHE (0.47) | ACHEPOLBGAATSHRCBX7 | |
| SCHEMBL5732721 | 0.95 | KDM4E (0.42) | ACHEHRH3NR4A2CYP2D6NPSR1 | |
| Hydrochloric Acid SCHEMBL425038 | 0.94 | KDM4E (0.41) | ACHEHRH3NR4A2CYP2D6NPSR1 | |
| SCHEMBL2996596 | 0.90 | MAPT (0.40) | ACHENR4A2CYP2C19NPSR1KDM4E | |
| SCHEMBL10252593 | 0.89 | NPY1R (0.42) | ACHEHRH3NR4A2NPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL424274 | 0.88 | NPY1R (0.41) | ACHEHRH3NPSR1KDM4ENPY1R | |
| SCHEMBL2996472 | 0.86 | POLB (0.42) | ACHEPOLBGAATSHRCBX7 | |
| SCHEMBL2996646 | 0.86 | GAA (0.42) | ACHEPOLBGAATSHRCBX7 | |
| SCHEMBL5732725 | 0.86 | ACHE (0.43) | ACHEPOLBGAATSHRHRH3 | |
| SCHEMBL10252715 | 0.85 | HRH3 (0.41) | HRH3NR4A2CYP2D6KDM4ENPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | claimed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | ACHE 3754/4885POLB 88/4885GAA 451/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | ACHE 3754/4885POLB 88/4885GAA 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.